Design and evaluation of 32P-labeled hydroxyapatite nanoparticles for bone tumor therapy

The clinical diagnosis and treatment of malignant bone tumors are still major clinical challenges due to their high incidence are difficulty. Targeted therapies have become a critical approach to treat bone tumors. In recent years, radiopharmaceuticals have been used widely and have shown potent and efficient results in treating bone tumors, among which P-32 and the labeled radiopharmaceuticals play an essential role. In this study, the P-32-labeled hydroxyapatite (HA) was prepared through chemical synthesis (P-32-Hap) and physical adsorption (P-32-doped-Hap). The in vitro stability of P-32-labeled HA was analyzed to assess the superiority of the new-found chemical synthesis. The radiolabeling yield and stability of chemical synthesis (97.6 +/- 0.5%) were significantly improved compared with physical adsorption (92.7 +/- 0.4%). Furthermore, the CT results corroborate that P-32-Hap (100 mu Ci) +DOX group has the highest tumor suppression rate and can effectively reduce bone destruction. The results corroborate the effectiveness of the chemical synthesis and validate the application of P-32-Hap in bone tumors. Therefore, P-32-Hap (100 mu Ci) + DOX may be an effective strategy for bone metastasis treatments.

Automated summary

The clinical diagnosis and treatment of malignant bone tumors remain challenging due to their high incidence and difficulty. Targeted therapies, especially radiopharmaceuticals, have shown promising results in treating bone tumors. In this study, P-32-labeled hydroxyapatite (HA) was prepared using chemical synthesis and physical adsorption. The chemical synthesis method exhibited higher radiolabeling yield and stability compared to physical adsorption. The results also demonstrated the effectiveness of P-32-Hap in treating bone tumors, suggesting that P-32-Hap combined with DOX may be an effective strategy for bone metastasis treatments.